
Could Ozempic have a protective effect against cancer?
A US study suggests Novo Nordisk’s GLP-1 receptor agonist Ozempic (semaglutide), which is approved as a treatment for diabetes and weight loss (as Wegovy), could reduce the risk of cancer. Ozempic has been in the spotlight recently following study data proving that patients taking it had… Read More












